Immunohistochemical analysis also demonstrated that treatment with MLN2238 significantly decreased the expression of the cell proliferation marker ki-67 and increased the expression of phospho-JNK (Thr183/Tyr185) in tumor tissues (Figure 8F). Here, MAPK8 is linked to neoplasm.